Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial

Vaccine

Volumn 35, Issue 46, 2017, Pages 6321-6328

  Ofori Anyinam, Opokua ^a   Leroux Roels, Geert ^b   Drame, Mamadou ^c   Aerssens, Annelies ^b   Maes, Cathy ^b   Amanullah, Arshad ^c   Schuind, Anne ^c   Li, Ping ^c,d   Jain, Varsha K ^c,e   Innis, Bruce L ^c,f  

^a GSK   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GLAXOSMITHKLINE   (United States)

^d Pfizer VRD   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f PATH   (United States)

Author keywords

Co administration; Comorbidity; Influenza; Non inferiority; Pneumococcal; Vaccine

Indexed keywords

AGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ADULT; ARTICLE; BELGIUM; CLINICAL PROTOCOL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRANCE; HEART DISEASE; HEMAGGLUTINATION INHIBITION; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFLUENZA; KIDNEY DISEASE; LIVER DISEASE; MIDDLE AGED; NEUROLOGIC DISEASE; OBESITY; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEROTYPE; SKIN REDNESS; SWELLING; VIRUS STRAIN; ADVERSE DRUG REACTION; AGED; BLOOD; CLINICAL TRIAL; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; MALE; MULTICENTER STUDY; PATHOLOGY; SINGLE BLIND PROCEDURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BELGIUM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; PLACEBOS; PNEUMOCOCCAL VACCINES; SINGLE-BLIND METHOD; VACCINES, INACTIVATED;

EID: 85030553078     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.012     Document Type: Article

References (42)

1. Zhou, H., Thompson, W.W., Viboud, C.G., Ringholz, C.M., Cheng, P.Y., Steiner, C., et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis 54 (2012), 1427–1436.
2. Thompson, W.W., Shay, D.K., Weintraub, E., Brammer, L., Bridges, C.B., Cox, N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 (2004), 1333–1340.
3. Thompson, W.W., Shay, D.K., Weintraub, E., Brammer, L., Cox, N., Anderson, L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003), 179–186.
4. European Centre for Disease Prevention and Control. Revised estimates of deaths associated with seasonal influenza in the US. 2010. Available from: http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=394. Accessed February 2017.
5. Ryan, J., Zoellner, Y., Gradl, B., Palache, B., Medema, J., Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24 (2006), 6812–6822.
6. Quandelacy, T.M., Viboud, C., Charu, V., Lipsitch, M., Goldstein, E., Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997–2007. Am J Epidemiol 179 (2014), 156–167.
7. Van Kerkhove, M.D., Cooper, M.J., Cost, A.A., Sanchez, J.L., Riley, S., Risk factors for severe outcomes among members of the United States military hospitalized with pneumonia and influenza, 2000–2012. Vaccine 33 (2015), 6970–6976.
8. Garg, S., Jain, S., Dawood, F.S., Jhung, M., Perez, A., D'Mello, T., et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005–2008. BMC Infect Dis, 15, 2015, 369.
9. Centers for Disease Control and Prevention. Pneumococcal disease. 2015. Available at: https://www.cdc.gov/pneumococcal/index.html Accessed February 2017.
10. Morrill, H.J., Caffrey, A.R., Noh, E., LaPlante, K.L., Epidemiology of pneumococcal disease in a national cohort of older adults. Infect Dis Ther 3 (2014), 19–33.
11. Verhaegen, J., Flamaing, J., De Backer, W., Delaere, B., Van Herck, K., Surmont, F., et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011. Euro Surveill 19 (2014), 14–22.
12. Wagenvoort, G.H., Knol, M.J., de Melker, H.E., Vlaminckx, B.J., van der Ende, A., Rozenbaum, M.H., et al. Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands. Vaccine 34 (2016), 334–340.
13. Kristensen, M., van Lier, A., Eilers, R., McDonald, S.A., Opstelten, W., van der Maas, N., et al. Burden of four vaccine preventable diseases in older adults. Vaccine 34 (2016), 942–949.
14. Chalmers, J.D., Campling, J., Dicker, A., Woodhead, M., Madhava, H., A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med, 16, 2016, 77.
15. van Hoek, A.J., Andrews, N., Waight, P.A., Stowe, J., Gates, P., George, R., et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 65 (2012), 17–24.
16. Kyaw, M.H., Rose, C.E. Jr., Fry, A.M., Singleton, J.A., Moore, Z., Zell, E.R., et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192 (2005), 377–386.
17. Walter, N.D., Taylor, T.H., Shay, D.K., Thompson, W.W., Brammer, L., Dowell, S.F., et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 50 (2010), 175–183.
18. Kyaw, M.H., Clarke, S., Jones, I.G., Campbell, H., Incidence of invasive pneumococcal disease in Scotland, 1988–99. Epidemiol Infect 128 (2002), 139–147.
19. Talbot, T.R., Poehling, K.A., Hartert, T.V., Arbogast, P.G., Halasa, N.B., Edwards, K.M., et al. Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med 118 (2005), 285–291.
20. Grabowska, K., Hogberg, L., Penttinen, P., Svensson, A., Ekdahl, K., Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis, 6, 2006, 58.
21. Pettigrew, M.M., Marks, L.R., Kong, Y., Gent, J.F., Roche-Hakansson, H., Hakansson, A.P., Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza A virus infection. Infect Immun 82 (2014), 4607–4619.
22. Skowronski, D.M., Masaro, C., Kwindt, T.L., Mak, A., Petric, M., Li, Y., et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25 (2007), 2842–2851.
23. Belongia, E.A., Kieke, B.A., Donahue, J.G., Greenlee, R.T., Balish, A., Foust, A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J Infect Dis 199 (2009), 159–167.
24. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe. 2012. Available at: http://ecdc.europa.eu/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf. Accessed February 2017.
25. Zhang, Y.Y., Tang, X.F., Du, C.H., Wang, B.B., Bi, Z.W., Dong, B.R., Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: a meta-analysis. Hum Vaccin Immunother 12 (2016), 3056–3064.
26. Nichol, K.L., The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 17:Suppl 1 (1999), S91–S93.
27. Dominguez, A., Castilla, J., Godoy, P., Delgado-Rodriguez, M., Saez, M., Soldevila, N., et al. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009–2010 and 2010–2011 seasons. Hum Vaccin Immunother 9 (2013), 865–873.
28. Chan, T.C., Hung, I.F., Luk, J.K., Shea, Y.F., Chan, F.H., Woo, P.C., et al. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc 13 (2012), 698–703.
29. Giese, C., Mereckiene, J., Danis, K., O'Donnell, J., O'Flanagan, D., Cotter, S., Low vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: the key role of GPs in recommending vaccination. Vaccine. 34 (2016), 3657–3662.
30. Hmamouchi, I., Winthrop, K., Launay, O., Dougados, M., Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine 33 (2015), 1446–1452.
31. Villarroel, M.A., Vahratian, A., Vaccination coverage among adults with diagnosed diabetes: United States, 2015. NCHS Data Brief 265 (2016), 1–8.
32. Valour, F., Cotte, L., Voirin, N., Godinot, M., Ader, F., Ferry, T., et al. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 32 (2014), 4558–4564.
33. Loubet, P., Kerneis, S., Groh, M., Loulergue, P., Blanche, P., Verger, P., et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 33 (2015), 3703–3708.
34. Kaljee, L.M., Kilgore, P., Prentiss, T., Lamerato, L., Moreno, D., Arshad, S., et al. “You need to be an advocate for yourself”: factors associated with decision-making regarding influenza and pneumococcal vaccine use among US older adults from within a large metropolitan health system. Hum Vaccin Immunother 13 (2017), 206–212.
35. Gilchrist, S.A., Nanni, A., Levine, O., Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health 102 (2012), 596–605.
36. Fletcher, T.J., Tunnicliffe, W.S., Hammond, K., Roberts, K., Ayres, J.G., Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ 314 (1997), 1663–1665.
37. Song, J.Y., Cheong, H.J., Tsai, T.F., Chang, H.A., Choi, M.J., Jeon, J.H., et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 33 (2015), 4647–4652.
38. Schwarz, T.F., Flamaing, J., Rumke, H.C., Penzes, J., Juergens, C., Wenz, A., et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Vaccine 29 (2011), 5195–5202.
39. Frenck, R.W. Jr., Gurtman, A., Rubino, J., Smith, W., van Cleeff, M., Jayawardene, D., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 19 (2012), 1296–1303.
40. Nath, K.D., Burel, J.G., Shankar, V., Pritchard, A.L., Towers, M., Looke, D., et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 9 (2014), 51–56.
41. Blumberg, E.A., Albano, C., Pruett, T., Isaacs, R., Fitzpatrick, J., Bergin, J., et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 22 (1996), 295–302.
42. Dorrell, L., Hassan, I., Marshall, S., Chakraverty, P., Ong, E., Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 8 (1997), 776–779.